Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)

Trial Identifier: D3258C00001
Sponsor: AstraZeneca
Start Date: January 2022
Primary Completion Date: February 2024
Study Completion Date: February 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
German Translation
English Translation
English Translation
Spanish Translation
Spanish Translation
French Translation
French Translation
Italian Translation
Japanese Translation
Dutch Translation
Dutch Translation
Polish Translation
Portuguese Translation
Ukrainian Translation
Vietnamese Translation
Chinese Translation

Trial Locations

Country Location
BR Sao Paulo, BR, 01327-001
ES Sevilla, ES, 41009
IT Milano, IT, 20122
IT Padova, IT, 35128
IT PISA, IT, 56124
JP Bunkyo-ku, JP, 113-8603
JP Maebashi-shi, JP, 371-8511
JP Ogaki-shi, JP, 503-8502
JP Shinjuku-ku, JP, 162-8655
NL Amsterdam, NL, 1105 AZ
PL Staszów, PL, 28-200
UA Kyiv, UA, 04050
US, IL Chicago, IL, US, 60611
US, MN Rochester, MN, US, 55905
US, NC Chapel Hill, NC, US, 27599
US, UT Salt Lake City, UT, US, 84107
US, UT Salt Lake City, UT, US, 84132
VN Hanoi, VN, 100000